Combined effect of CYP2B6 and NAT2 genotype on plasma efavirenz exposure during rifampin-based antituberculosis therapy in the STRIDE study.
Clin Infect Dis
; 60(12): 1860-3, 2015 Jun 15.
Article
em En
| MEDLINE
| ID: mdl-25722197
In STRIDE, slow metabolizer CYP2B6 and NAT2 genotypes were each associated with increased plasma efavirenz concentrations during antituberculosis therapy. Concentrations were greater on therapy than off therapy in 58% with CYP2B6 and 93% with NAT2 slow metabolizer genotypes. Individuals with slow metabolizer genotypes in both genes had markedly elevated concentrations.
Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Arilamina N-Acetiltransferase
/
Rifampina
/
Tuberculose
/
Benzoxazinas
/
Citocromo P-450 CYP2B6
/
Antituberculosos
Limite:
Female
/
Humans
/
Male
País/Região como assunto:
Africa
/
America do sul
/
Peru
Idioma:
En
Revista:
Clin Infect Dis
Assunto da revista:
DOENCAS TRANSMISSIVEIS
Ano de publicação:
2015
Tipo de documento:
Article
País de publicação:
Estados Unidos